Variable | Cefazolin (n = 110) | Ertapenem (n = 113) | P |
---|---|---|---|
Age in years (mean, ±SD) | 54.02 (13.6) | 53.99 (14.7) | 1 |
Male sex | 61 (55%) | 65 (57%) | 0.7 |
Donor type | |||
Deceased | 53 (48%) | 61 (54%) | 0.4 |
Live | 57 (52%) | 52 (46%) | |
Donor’s cause of death | |||
Anoxia | 14 (26%) | 8 (15%) | 0.1 |
CVA | 31 (58%) | 42 (80%) | |
Trauma | 7 (13%) | 2 (4%) | |
Other | 1 (2%) | 0 | |
Median ischemia time (minutes, ±SD) | 473 (470) | 491 (434) | 0.4 |
Diabetes mellitus | 24 (22%) | 26 (23%) | 0.8 |
End-stage renal disease | |||
Glomerulonephritis | 9 (8%) | 6 (5%) | 0.9 |
Diabetes mellitus | 17 (16%) | 17 (16%) | |
Hypertension | 19 (17%) | 16 (14%) | |
Cystic kidney disease | 18 (16%) | 17 (15%) | |
Other Urologic | 8 (7%) | 10 (9%) | |
Other cause | 23 (21%) | 23 (20%) | |
Unkown/missing | 16 (15%) | 24 (21%) | |
Prior transplantation | 18 (16%) | 22 (19%) | 0.6 |
Immunosuppression regimen | |||
CNI + MMF+ CS | 72 (65%) | 64 (57%) | 0.3 |
CNI + mTOR+ CS | 34 (31%) | 46 (41%) | |
Other | 4 (4%) | 3 (2%) | |
Induction | |||
None | 18 (16%) | 9 (8%) | 0.4 |
Basiliximab | 26 (24%) | 55 (49%) | |
Anti-lymphocyte globulines | 66 (60%) | 49 (43%) | |
Pre-transplant rituximab | 13 (12%) | 13 (11%) | 0.9 |